Astrazeneca’s Breast Cancer Treatment Passes FDA Regulations

AstraZeneca’s new drug therapeutic targeting the most prevalent form of breast cancer has been accepted by The U.S. Food and Drug Administration. Partnered with an earlier medication, Truqap offers an additional choice of therapy to patients. 

Trupaq has been introduced as a new breast cancer treatment, rivalling current medications such as Trodelvy from Gilead and Enhertu from AstraZeneca-Daiichi Sankyo. 

In a last phase trial, the medication exceeded time spent without the patient’s cancer progressing by just over 7 months. 

This pharmaceutical is targeted at those whose tumor has reappeared or gotten worse post hormone treatment. 

In the US, breast cancer is the most prevalent cancer identified in women and one of the most common causes of cancer-related deaths.  

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.